Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 1/20 | 0.83 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.57 |
| ▸ | PLA2G6 | O60733 | 2/20 | 0.50 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 4/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | F2 | P00734 | 2/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.43 |
| ▸ | LYPLA1 | O75608 | 1/20 | 0.38 |
| ▸ | LYPLA2 | O95372 | 1/20 | 0.38 |
| ▸ | ABHD16A | O95870 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16551964 | 0.91 | FASN (0.68) | FASNCTRB1PLA2G6PLA2G4AMAOB | |
| SCHEMBL10073526 | 0.91 | FASN (1.00) | FASNCTRB1PLA2G6PLA2G4AF2 | |
| SCHEMBL10083649 | 0.91 | FASN (1.00) | FASNCTRB1PLA2G6PLA2G4AF2 | |
| SCHEMBL16551923 | 0.86 | FASN (0.83) | FASNCTRB1PLA2G6PLA2G4AMAOB | |
| SCHEMBL15012874 | 0.81 | FASN (0.81) | FASNCTRB1PLA2G6PLA2G4AF2 | |
| SCHEMBL15012876 | 0.81 | FASN (0.81) | FASNCTRB1PLA2G6PLA2G4AF2 | |
| SCHEMBL16551935 | 0.81 | FASN (0.53) | FASNCTRB1PLA2G6PLA2G4AF2 | |
| SCHEMBL28541028 | 0.81 | FASN (0.79) | FASNCTRB1PLA2G6PLA2G4AF2 | |
| SCHEMBL31138044 | 0.77 | FASN (0.73) | FASNCTRB1PLA2G6PLA2G4AF2 | |
| SCHEMBL17973346 | 0.77 | FASN (0.73) | FASNCTRB1PLA2G6PLA2G4AF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11376242-B2 | Methods and compositions for treating obesity and/or diabetes and for identifying candidate treatment agents | THE J. DAVID GLADSTONE INSTITUTES (US) | 2022-07-05 | — | — | US | disclosed |
| US-20190000817-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY AND/OR DIABETES AND FOR IDENTIFYING CANDIDATE TREATMENT AGENTS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE | 2019-01-03 | — | — | US | disclosed |
| US-20160221977-A1 | ANTIBACTERIAL BETA-LACTONES, AND METHODS OF IDENTIFICATION, MANUFACTURE AND USE | BROWN UNIVERSITY (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160221977-A1 | ANTIBACTERIAL BETA-LACTONES, AND METHODS OF IDENTIFICATION, MANUFACTURE AND USE | BROWN UNIVERSITY (US) | 2016-08-04 | — | — | US | disclosed |
| WO-2015031300-A1 | ANTIBACTERIAL BETA-LACTONES, AND METHODS OF IDENTIFICATION, MANUFACTURE AND USE | BROWN UNIVERSITY (US) | 2015-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11376242-B2 | Methods and compositions for treating obesity and/or diabetes and for identifying candidate treatment agents | PNLIP, LIPC, IAPP | FASN 853/4885CTRB1 32/4885PLA2G6 1875/4885 |
| US-20160221977-A1 | ANTIBACTERIAL BETA-LACTONES, AND METHODS OF IDENTIFICATION, MANUFACTURE AND USE | CBR1, CBR3, NR2C2 | FASN 1268/4885CTRB1 1388/4885PLA2G6 4292/4885 |
| US-20190000817-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY AND/OR DIABETES AND FOR IDENTIFYING CANDIDATE TREATMENT AGENTS | PNLIP, LIPC, IAPP | FASN 853/4885CTRB1 32/4885PLA2G6 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.